About: Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial
Creator	Liu, Quan Xu, Xi Zhang, Ying Li, Xiaodong Zhang, Peng Zhu, Zheng Yang, Lu Li, Ke Li, Lian Zhang, Qing Li, Li, Zeng Ke, Jia Li, Xiuyang Lian, Lian, Fengmei Tian, Jiaxing Tong, Xiaolin Wu, Haoran Zheng, Yujiao Fan, An Jiang, Manhong Lang, Suping Li, Chengyin Lin, Jiaran Liu, Binbin Lv, Yi Min, Xiaojun Peng, Miao Xiao, Mingzhong Yan, Dengying Zeng, Kun Zhou, Yana Zhu, Jinyue Li#, Xiaodong Lian#, Fengmei Lv, Min Tong#, Xiaolin
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: With the global epidemic of coronavirus disease (COVID-19), China has made progress in the prevention and control of the epidemic, and traditional Chinese medicine (TCM) has played a key role in dealing with the disease’s effects on the respiratory system. This randomized controlled clinical trial evaluated the clinical efficacy and prognosis of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in patients with COVID-19. METHODS: A total of 283 patients participated in this clinical trial, and participants were randomly assigned to receive either 1) Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules or 2) Linahua granules, both combined with western medicine, or 3) western medicine alone for 14 days. At the end of the trial, the improvement and resolution rates of clinical symptoms and the rate of patients who progressed to severe disease status were evaluated. RESULTS: After 14 days of treatment, there was no significant difference in the improvement rate of clinical symptoms among the three groups (P > 0.05). Huoxiang Zhengqi dropping pills combined with Lianhua Qingwen granules has advantages in the treatment of nausea, vomiting and limb soreness. During treatment, all participants were treated with western medicine, and there was a significant difference in the use of macrolides among the three groups (P < 0.05). Specifically, the utilization rate of antibiotics in the western medicine group was significantly greater than that of the other two groups. Among the 182 diagnosed patients who completed this clinical trial, 13 patients progressed to severe disease, including one case in the Huoxiang + Lianhua group (1.6%), five cases in the Lianhua group (8.6%), and seven cases in the western medicine group (11.1%). There was no statistical differences in this rate among the three groups (P > 0.05). However, the proportion of patients who progressed to severe disease in the Huoxiang + Lianhua group was the lowest, suggesting that the combination of TCM with western medicine has a potential advantage in improving the prognosis of patients with COVID-19. CONCLUSION: The use of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules combined with western medicine may have clinical advantages for COVID-19 patients in improving clinical symptoms, reducing utilization rate of anti-infective drugs, and improving patient prognosis, which could pave the way for the use of complementary medicine in treating this infection.
has issue date	2020-08-08(xsd:dateTime)
bibo:doi	10.1016/j.phrs.2020.105126
bibo:pmid	32781283
has license	no-cc
sha1sum (hex)	2c0d8b06224bbaba025ef60f857bd932e7de1fc8
schema:url	https://doi.org/10.1016/j.phrs.2020.105126
resource representing a document's title	Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial
has PubMed Central identifier	PMC7414728
has PubMed identifier	32781283
schema:publication	Pharmacol Res
resource representing a document's body	covid:2c0d8b06224bbaba025ef60f857bd932e7de1fc8#body_text
is schema:about of	named entity 'dealing' named entity 'dropping' named entity 'randomized' named entity 'COVID-19' named entity 'CHINA' named entity '27S' named entity 'KEY' named entity 'PROGRESS' named entity 'Qingwen' named entity 'Background' named entity 'prognosis' named entity 'Lianhua' named entity 'China' named entity 'prognosis' named entity 'coronavirus disease' named entity 'COVID' named entity 'randomized controlled trial' named entity 'TCM' named entity 'COVID-19' named entity 'anti-infective' named entity 'antiviral drugs' named entity 'western medicine' named entity 'cell membrane' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'drug allergies' named entity 'adverse events' named entity 'clinical evidence' named entity 'patchouli' named entity 'cough' named entity 'antiviral drugs' named entity 'ketone' named entity 'bronchial asthma' named entity 'COVID' named entity 'COVID-19' named entity 'lipopolysaccharides' named entity 'TCM' named entity 'sample size' named entity 'fatigue' named entity 'infectious diseases' named entity 'virus' named entity 'clinical trial' named entity 'epidemic' named entity 'TCM' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software